Prognostication refinement in NPM1 ‐mutated acute myeloid leukemia stratified by FLT3 ‐ITD status with different induction doses of cytarabine
Cancer Medicine · 2023
DOI: 10.1002/cam4.5704 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Biao Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou, China. Hauptthemen laut MEDLINE: Nuclear Proteins, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
We aimed to retrospectively discern the heterogeneity of outcomes from clinicopathological characteristics and next‐generation sequencing (NGS) data in adult patients with NPM1‐ mutated ( NPM1 mut ) acute myeloid leukemia (AML) induced with standard‐dose (SD, 100–200 mg/m 2 ) and intermediate‐dose (ID, 1000–2000 mg/m 2 ) cytarabine arabinose (Ara‐C).
Methods
In the entire cohort and FLT3 ‐ITD subgroups, multivariate Logistic and Cox regression analyses were used to analyze the comprehensive complete remission (cCR) rate after one or two induction cycles, event‐free survival (EFS), and overall survival (OS).
Results
Among a total of 203 NPM1 mut patients evaluable for clinical outcome, 144 (70.9%) received a first SD‐Ara‐C induction and 59 (29.1%) received ID‐Ara‐C induction. Early death was recorded in seven (3.4%) after one or two cycles of induction. Focusing analysis on the NPM1 mut / FLT3 ‐ITD (−) subgroup, independent factors showing inferior outcome were presence of TET2 mutation [cCR rate, OR = 12.82 (95%CI 1.93–85.28), p = 0.008; EFS, HR = 2.92 (95%CI 1.46–5.86), p = 0.003], increasing age [EFS, HR = 1.49 (95%CI 1.10–2.02), p = 0.012 by every 10‐years elevation], white blood cell count ≥60 × 10 9 /L [EFS, HR = 3.30 (95%CI 1.63–6.70), p = 0.001], and ≥4 mutated genes at initial diagnosis [OS, HR = 5.54 (95%CI 1.77–17.33), p = 0.003]. In contrast, when focusing on the NPM1 mut / FLT3 ‐ITD (+) subgroup, factors showing superior outcome were ID‐Ara‐C induction [cCR rate, OR = 0.20 (95%CI 0.05–0.81), p = 0.025; EFS, HR = 0.27 (95%CI 0.13–0.60), p = 0.001] and allo‐transplantation [OS, HR = 0.45 (95%CI 0.21–0.94), p = 0.033]. Factors showing inferior outcome included CD34 (+) [cCR rate, OR = 6.22 (95%CI 1.86–20.77), p = 0.003; EFS, HR = 2.01 (95%CI 1.12–3.61), p = 0.020] and ≥5 mutated genes [OS, HR = 2.85 (95%CI 1.33–6.10), p = 0.007].
Conclusion
We conclude that TET2 (+) , age, and white blood cell count convey an outcome risk modulation for AML with NPM1 mut / FLT3 ‐ITD (−) , as does CD34 and ID‐Ara‐C induction for NPM1 mut / FLT3 ‐ITD (+) . The findings permit re‐stratification of NPM1 mut AML into distinct prognostic subsets to guide risk‐adapted individualized treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou, China.
- Blood Research Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
ORCID-Profile: Biao Wang
Zitieren
APA
Wang, B., Hua, X., Zhang, J., Gu, W., & Li, H. (2023). Prognostication refinement in NPM1 ‐mutated acute myeloid leukemia stratified by FLT3 ‐ITD status with different induction doses of cytarabine. Cancer Medicine. https://doi.org/10.1002/cam4.5704
Vancouver
Wang B, Hua X, Zhang J, Gu W, Li H. Prognostication refinement in NPM1 ‐mutated acute myeloid leukemia stratified by FLT3 ‐ITD status with different induction doses of cytarabine. Cancer Medicine. 2023. doi:10.1002/cam4.5704
BibTeX
@article{Wang2023,
author = {Wang, Biao and Hua, Xiaoying and Zhang, Jihong and Gu, Weiying and Li, Haiqian},
title = {Prognostication refinement in NPM1 ‐mutated acute myeloid leukemia stratified by FLT3 ‐ITD status with different induction doses of cytarabine},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5704}
}
EUVIMED